Global Alpha Capital Management Ltd. Invests $806,000 in Haemonetics Co. (NYSE:HAE)

Global Alpha Capital Management Ltd. purchased a new position in Haemonetics Co. (NYSE:HAE - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,025 shares of the medical instruments supplier's stock, valued at approximately $806,000.

Several other large investors also recently added to or reduced their stakes in the stock. Quarry LP acquired a new position in Haemonetics during the 2nd quarter worth about $39,000. Covestor Ltd increased its stake in Haemonetics by 184.8% in the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 438 shares during the last quarter. Daiwa Securities Group Inc. purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $82,000. Canada Pension Plan Investment Board acquired a new stake in shares of Haemonetics during the second quarter worth about $83,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Haemonetics in the 1st quarter valued at $86,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HAE has been the subject of a number of recent research reports. BTIG Research started coverage on Haemonetics in a research report on Tuesday, September 10th. They set a "buy" rating and a $112.00 price objective for the company. Bank of America began coverage on Haemonetics in a report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price objective for the company. Barrington Research restated an "outperform" rating and set a $108.00 price objective on shares of Haemonetics in a research report on Friday, November 8th. Citigroup lowered their price target on Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a report on Thursday, August 22nd. Finally, CL King initiated coverage on shares of Haemonetics in a research note on Friday, September 13th. They set a "buy" rating and a $116.00 price target on the stock. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $107.88.

Haemonetics Stock Up 0.1 %

HAE stock traded up $0.09 during trading on Wednesday, reaching $84.92. The stock had a trading volume of 618,035 shares, compared to its average volume of 556,985. The firm has a fifty day moving average price of $78.07 and a 200 day moving average price of $82.52. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The company has a market capitalization of $4.26 billion, a P/E ratio of 35.21, a PEG ratio of 1.39 and a beta of 0.32. Haemonetics Co. has a 1-year low of $70.25 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. During the same period in the previous year, the business earned $0.99 EPS. Haemonetics's revenue for the quarter was up 8.6% compared to the same quarter last year. On average, equities analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.